MedTrace Logo

Treatment of Poor Ovarian Responders With Corifollitropin Alfa Followed by hpHMG in a Short GnRH Agonist Protocol

NCT01732068 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 51

Last updated 2013-05-09

No results posted yet for this study

Summary

The purpose of the present study is to examine the level of ovarian response and the pregnancy rates among poor ovarian responders treated with a novel treatment protocol with 150μg corifollitropin alfa followed by 300IU hMG in a short GnRH agonist protocol.

Conditions

Interventions

DRUG

Triptorelin

Triptorelin 0.1 mg/1 ml solution daily from day 1 or 2 of the cycle onwards

DRUG

Corifollitropin alfa

Corifollitropin alfa 150μg (single dose) on day 2 or 3 of the cycle

DRUG

hpHMG

300IU hMG daily from day 7 following Corifollitropin alfa until the day of ovulation triggering

Sponsors & Collaborators

  • Universitair Ziekenhuis Brussel

    lead OTHER

Principal Investigators

  • Nikolaos P Polyzos, MD PhD · Universitair Ziekenhuis Brussel

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
FEMALE
Healthy Volunteers
No

Timeline & Regulatory

Start
2012-07-31
Primary Completion
2013-05-31
Completion
2013-05-31

Countries

  • Belgium

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01732068 on ClinicalTrials.gov